VANCOUVER, BC, Aug. 23, 2021 /PRNewswire/ -- The global viral vector and plasmid manufacturing market size is expected to reach USD 1.12 billion in 2027 at a CAGR of 14.3% during the forecast period, according to the latest report by Emergen Research. Increasing research and development activities in biopharmaceutical sector, growing demand for viral-vector based vaccines, rising use of plasmid DNA in developing advanced genetic therapy to treat severe and chronic indications, and increasing number of product approval from the regulatory authorities such as the FDA are key factors expected to drive market revenue growth over the forecast period.
Viral vector and plasmid DNA are critical tools used by molecular biologists and researchers to deliver genetic material into cells – a process known as transduction. Viral vectors are extensively used in molecular biology research, in gene therapy, and in development of vaccines. As compared to conventional methods, transduction ensures 100% infection of cells without interfering with cell viability. Using plasmid DNA with virus-mediated delivery has proven to be extremely beneficial for research. Viral vectors facilitate the delivery of specific genes into normal cells and hard-to-transfect mammalian cells, and can also deliver the genetic material to specific cells in a particular organism. Increasing advancements in molecular research and technological developments in techniques and procedures has significantly contributed to revenue growth of the market.
Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/14
Increasing focus on viral vector based vaccines, especially amid the COVID-19 pandemic, to deliver genetic material coding for specific antigen is also a key factor fueling the revenue growth of the market. Viral vectors don't cause infection with either the viral particle used or source of the antigen and induce a robust immune response and this has led to increasing focus on the use of viral vectors and plasmid DNA. However, complexities of large-scale production of viral vector and plasmid DNA, lack of expertise, and high capital investment are some key factors expected to restrain market growth to a certain extent during the forecast period.
Some Key Highlights in the Report:
- Adenovirus vector segment is expected to account for largest revenue share in the global market over the forecast period owing to increasing focus on and application of adenovirus in gene therapies, vaccine manufacturing, and in research and development activities.
- Downstream processing segment is expected to register robust revenue CAGR over the forecast period owing to increasing advancements in downstream processing, introduced of advanced chromatography products and novel technologies, and development of cost- and time-efficient technologies.
- Gene therapy segment is expected to account for significantly large revenue share in the global market between 2020 and 2027 owing to increasing use of viral vector to deliver specific genes to cells in gene therapy, rapid advancements in gene therapy, and rising number of gene therapy product approvals by regulatory authorities.
- Pharmaceutical and biotechnology firms segment is expected to register considerable revenue growth over the forecast period owing to increasing number of research and development activities, development of new therapies and vaccine pipeline, and increasing number of gene therapy projects.
- North America accounted for largest revenue share in 2019 and is expected to register significant revenue growth going ahead owing to presence of large number of biotech and pharmaceutical companies, implementation of favorable regulatory policies, introduction of advanced viral vector-based therapies, and rising number of product approvals and pipeline therapeutics.
- Key companies in the market include Brammer Bio, Cobra Biologics, Cell, and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Unique NV.
Make Payment [Buy your Exclusive copy]@ https://www.emergenresearch.com/select-license/14
For the purpose of this report, Emergen Research has segmented the global viral vector and plasmid manufacturing market on the basis of vector type, workflow, disease, application, end-use, and region:
Vector Type Outlook (Revenue, USD Billion; 2017-2027)
- Plasmid DNA
Workflow Outlook (Revenue, USD Billion; 2017-2027)
- Upstream Processing
- Downstream Processing
Disease Outlook (Revenue, USD Billion; 2017-2027)
- Genetic Disorders
- Infectious Diseases
Application Outlook (Revenue, USD Billion; 2017-2027)
- Antisense & RNAi
- Gene Therapy
- Cell Therapy
End-Use Outlook (Revenue, USD Billion; 2017-2027)
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/viral-vector-and-plasmid-manufacturing-market
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
Explore more reports offered by Emergen Research:
The global In-Vitro Diagnostics Market size was valued at USD 83.37 Billion in 2020 and is anticipated to reach USD 118.44 Billion by 2028 at a CAGR of 4.4%. The demand for this type of diagnosis is increasing due to the rise in the number of people suffering from chronic diseases. Infectious diseases, chronic diseases, sexually transmitted diseases, genetic testing, oncology are all increasing the demand for diagnostic tests.
The Global Cancer Immunotherapy Market size and is anticipated to reach USD 153.03 Billion by 2027 at a CAGR of 10.1%, from its valuation of USD 78.04 Billion in 2019. The market is growing at a substantial pace due to the patients' growing acceptance and inclination towards the newly invented advanced treatments over the conventional ones.
The global biologics market size was valued at USD 270.55 Billion in 2019 and is forecasted to reach USD 477.15 Billion by 2027 at a CAGR of 7.3%. The Biologics market is experiencing a rapid growth attributable to a growing demand for monoclonal antibodies, recombinant hormones/proteins, gene-based &; cellular-based biologics, vaccines, and molecular therapy, in the treatment of diseases including cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others.
The global radiotherapy market is forecasted to grow at a rate of 3.4% from USD 5.82 billion in 2019 to USD 7.65 Billion in 2027. The market is witnessing rising growth due to the rising prevalence of cancer. According to the Cancer Research U.K. about 17 million new cases of cancer worldwide and around 9.6 million death due to cancer in the region were registered in 2018.
The global viral vector and plasmid manufacturing market size was valued at USD 358.4 million in 2019 and is anticipated to reach USD 1.12 Billion by 2027 at a CAGR of 14.3%. Advanced treatments, including gene therapy using multiple viral and non-viral vectors, have paved a way to treat many heritable and inherited diseases that previously lacked successful treatment modalities.
The global clinical biomarkers market is expected to register a double-digit CAGR of 10.2% and reach a market size of USD 38.79 billion by 2027. High cancer prevalence has been resulting in increasing research and development initiatives globally, and this is a key factor expected to drive market growth. Technical advancements to develop biomarker-based clinical diagnostics, growing number of CROs, and increasing healthcare burden, especially related to rising prevalence of obesity, diabetes, and cardiovascular diseases, driven by sedentary lifestyle, unhealthy diet, tobacco use, exposure to secondhand smoke, lack of physical activity, and excessive alcohol use are among other key factors expected to drive market growth.
The global companion diagnostics market is forecasted to grow at a rate of 18.9% in terms of value, from USD 2.43 billion in 2019 to reach USD 9.72 billion by 2027. Increasing incidences of harmful product reactions would be helpful for the development of the business. Adverse reactions worsen the current state of the individual and raise the level of morbidity and mortality.
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Read Full Press Release@ https://www.emergenresearch.com/press-release/global-viral-vector-and-plasmid-manufacturing-market